Whether higher IL-6 levels resulted from administration of tocilizumab in COVID-19 patients with elevated baseline IL-6 will lead to central nervous system symptoms or other adverse events is worth further exploration, since tocilizumab might be difficult to penetrate the complete blood–brain barrier and then block the IL-6 signal in the brain. Here, IL6 is linked to COVID-19.